Product Details

Uniprot No.

Target Names

Alternative Names

bacteria-expressed kinase antibody; BBDS antibody; BEK antibody; BEK fibroblast growth factor receptor antibody; BFR1 antibody; CD332 antibody; CD332 antigen antibody; CEK3 antibody; CFD1 antibody; Craniofacial dysostosis 1 antibody; ECT1 antibody; FGF receptor antibody; FGFR 2 antibody; FGFR-2 antibody; Fgfr2 antibody; FGFR2_HUMAN antibody; Fibroblast growth factor receptor 2 antibody; Hydroxyaryl protein kinase antibody; Jackson Weiss syndrome antibody; JWS antibody; K SAM antibody; K-sam antibody; Keratinocyte growth factor receptor 2 antibody; Keratinocyte growth factor receptor antibody; KGFR antibody; KSAM antibody; protein tyrosine kinase; receptor like 14 antibody; soluble FGFR4 variant 4 antibody; TK14 antibody; TK25 antibody

Species Reactivity

Human

Immunogen

Recombinant Human FGFR2 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

18D12

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Tested Applications

ELISA, WB, IHC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase that plays essential roles in embryonic development, tissue repair, and cellular signaling cascades. This receptor mediates critical processes including cell proliferation, differentiation, and migration, making it a focal point in cancer biology, developmental studies, and stem cell research. Dysregulation of FGFR2 signaling has been implicated in various malignancies and developmental disorders, including craniosynostosis syndromes, positioning this target as highly relevant for both basic research and translational investigations.

This recombinant monoclonal antibody, clone 18D12, offers the reproducibility and consistency that demanding experimental workflows require. Generated against recombinant human FGFR2 protein and produced using recombinant technology, this antibody provides sequence-defined specificity with minimal lot-to-lot variation, ensuring your results remain comparable across extended studies. The human IgG1 isotype format and affinity chromatography purification deliver a reagent optimized for reliable performance.

Validation studies demonstrate robust detection in Western blot applications using HeLa and HT29 whole cell lysates, with an observed band at approximately 41 kDa. This molecular weight corresponds to one of the known FGFR2 isoforms, as the receptor exists in multiple splice variants with predicted sizes ranging from approximately 28 to 92 kDa. Immunohistochemistry validation confirms effective staining in paraffin-embedded human lung cancer and liver tissue sections, providing researchers with flexibility across both biochemical and morphological analyses.

Whether investigating FGFR2 signaling in oncology models, exploring its role in cardiovascular development, or examining receptor dynamics in stem cell differentiation, this antibody supports diverse research applications with the consistency recombinant technology provides.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Gene References into Functions

The results showed no association between two SNPs, rs1219648 and rs2981582, and breast cancer risk, although in a stratified analysis rs2981582 strongly associated with premenopausal and ER-positive breast cancer in Chinese patients. PMID: 30480917
The consequent appearance of the mesenchymal FGFR2c variant in the epithelial context would drive early steps of carcinogenesis. PMID: 29068468
FGFR2 was shown to be markedly overexpressed in gastric cancer tissues and correlated with a high risk of lymph node metastasis and late clinical stage. FGFR2 was negatively associated with TSP4 and FGFR2 activation could downregulate TSP4 expression, which played an important role in the proliferation, invasion and migration of gastric cancer cells. PMID: 30355943
In male breast cancer, smoking habits had a significant effect on overall survival at 10 years. In the same multivariate analysis, we found a significantly higher overall survival in cases with FGFR2 rs2981582 variant in the dominant transmission model A sensitivity analysis with left truncation showed similar results. PMID: 29709729
Results showed that HER2 and FGFR2 are regulated by DDX6 at the post-transcriptional step in gastric cancer. PMID: 29987267
High FGFR2 expression is associated with epithelial ovarian cancer cell proliferation and invasion. PMID: 29970688
There is a wide spectrum of mutations in FGFR2 shown to be causative for Pfeiffer syndrome. Here we report the first Chinese three-generation family with FGFR2 mutation c.514_515delGCinsTT (p.Ala172Phe). PMID: 29782338
It was concluded that miR494 inhibited the cancer initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2positive gastric cancer. PMID: 29786108
Patients with very strong FGFR2 mRNA expression showed more homogeneous FGFR2 mRNA expression compared to patients with lower FGFGR2 mRNA expression PMID: 28852882
provide a comprehensive update on FGFR2-related syndromic craniosynostosis PMID: 29230096
The mutations were not present in any of the unaffected family members or unrelated control subjects. These findings expand the mutation spectrum of FGFR2, and are valuable for genetic counseling in addition to prenatal diagnosis in patients with Crouzon syndrome. PMID: 28901406
Fibroblast growth factor receptor 2 (FGFR2) splice site variants were identified in eight patients with Crouzon or Pfeiffer syndrome. PMID: 26841243
Data suggest that the SOX9 transcription factor (SOX9)-fibroblast growth factor receptor 2 (FGFR2b) feed-forward loop has a lineage dependency role in pancreatic ductal adenocarcinoma (PDAC). PMID: 28796141
this study reports for the first time the p.W290G mutation in patients with PS. Based on clinical features, genetic, and computational analysis and genotype-phenotype association studies PMID: 28815901
Studies indicate that switching from fibroblast growth factor receptor 2 (FDFR-2) IIIb to IIIc variants correlates with the aggressiveness of the cancers via epithelial-mesenchymal transition [Review]. PMID: 28930565
These results unveil the complexity of ER regulation by FGFR2-mediated signaling likely to be associated with BCa resistance to endocrine therapy. PMID: 28869838
Study report that 5-10% of epidermal nevi harbor embryonic postzygotic FGFR2 activating mutations. PMID: 27103312
this study identified an FGFR2 in two Chinese patients with syndromic craniosynostosis. The finding expands the reported mutation spectrum of FGFR2, and is of great value for genetic counseling and prenatal diagnosis in families with syndromic craniosynostosis. PMID: 28849010
Through a stratification analysis, 5q11.2/MAP3K1 (rs16886034, rs16886364, rs16886397, rs1017226, rs16886448) and 7q32.3/LINC-PINT (rs4593472) were associated with Luminal A, and 10q26.1/FGFR2 (rs35054928) was associated with Luminal B. PMID: 28408616
SNORD126 activates the PI3K-AKT pathway by upregulation of FGFR2. PMID: 27913571
This study reveals a direct binding event and characterizes the role of TRPA1 ankyrin repeats in regulating FGFR2-driven oncogenic process; a mechanism that is hindered by miRNA-142-3p PMID: 29038531
Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy. PMID: 27802183
This meta-analysis of case-control studies provides strong evidence that FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms were significantly associated with the BC risk. PMID: 27966449
we further refine the influence of variants in the FGFR2 locus with respect to molecular characteristics of breast tumors, in that they are more strongly associated with estrogen receptor status among cancers without amplification of the HER2 gene. PMID: 27764800
Suggest FGFR2 as a novel acute myeloid leukemia susceptibility gene with a haplotype TT (rs7090018 and rs2912759) showing significant association with AML. PMID: 27903959
Result demonstrated that FGFR2 high-expression was significantly associated with unfavorable prognosis of gastric adenocarcinoma and that SPRY2 could inhibit FGFR2-induced ERK phosphorylation and suppress FGFR2-elicited gastric cancer cell proliferation and invasion. PMID: 28002800
By means of structural (X-ray and NMR) and functional characterization of pathogenic gain-of-function mutations affecting the FGF receptor (FGFR) tyrosine kinase domain, the authors elucidated a long-distance allosteric network composed of four interconnected sites termed the 'molecular brake', 'DFG latch', 'A-loop plug', and 'alphaC tether'. The first three sites repress the kinase from adopting an active conformation... PMID: 28166054
Besides, we found miR-628-5p targeted at and down-regulated the expression of fibroblast growth factor receptor 2 (FGFR2). FGFR2 expressed higher in ovarian cancer tissues and was correlated with worse prognosis. Our findings indicated that miR-628-5pplays an important role in ovarian cancer stem cell driven tumorigenesis. PMID: 29229394
Mandibular growth in children with FGFR2 mutations is not normal with impairments found in forward sagittal growth and skull base widening PMID: 28468153
Inhibiting Fgf-R partly reversed alphavbeta3 integrin activity in Mll-Ell+ progenitor cells. PMID: 27340869
In gastric cancer, FGFR2 protein overexpression predicts gene amplification and poor survival. PMID: 27230412
Her2, cMet and FGFR2 statuses were profiled in gastric cancer (GC) patients and the -derived tumor xenograft(PDX) models. PMID: 28292264
We demonstrate that the bent bone dysplasia syndrome mutations in FGFR2 p.M391R and p.Y381D augment the ability of FGFR2 to epigenetically activate rDNA. Mutations p.M391R and p.Y381D activate the p53 nucleolar stress response pathway and alter FGFR2-mediated activation of ribosome biogenesis. PMID: 28595297
Polyclonal secondary FGFR2 mutations represent an important clinical resistance mechanism to protein kinase inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma. PMID: 28034880
CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription. PMID: 27107424
a novel identical postzygotic activating FGFR2 mutation in two unrelated fetuses with papillomatous pedunculated sebaceous naevus. PMID: 27095246
Findings suggest fibroblast growth factor receptor 2 (FGFR2) as a therapeutic target for esophagogastric junction (EGJ) adenocarcinoma. PMID: 26933914
Description of these patients expands the prenatal and postnatal findings of Bent Bone Dysplasia-FGFR2 type and adds to the phenotypic spectrum among all FGFR2 disorders. PMID: 27240702
Our results imply that the same FGFR2 mutations result in diverse phenotypes, and that genetic studies are recommended not only for obviously affected individuals but also for family members with apparently normal phenotype or non-specific subtle abnormal phenotype. PMID: 27683237
Liensinine inhibits FGFR2 activity. PMID: 28132898
FGFR2-ACSL5 fusion is associated with resistance to LY2874455 in FGFR2-amplified gastric cancer . PMID: 28122360
FGFR2 mutation is associated with endometrial carcinoma progression and abdominopelvic metastasis. PMID: 27348297
FGFR inhibitors, particularly BGJ398, are therapeutic options for cholangiocarcinoma patients harboring FGFR2-CCDC6 fusions. PMID: 27216979
High FGFR2 expression is associated with Gastric Cancers. PMID: 27197184
Two novel FGFR 2 gene missense mutations in Chinese patients with Crouzon syndrome were identified. PMID: 27430617
Incidence of progression (progressed, recurred or died from disease) of endometrioid endometrial cancer was significantly more prevalent (32/125, 26%) among patients with FGFR2 mutation versus wild type (120/848, 14%; p<0.001, Chi-square test). PMID: 28314589
We show that this stabilizes the tyrosine and primes it for the catalytic phosphotransfer, and it may lower the activation barrier of the phosphotransfer reaction. Our work demonstrates the value of including dynamic information gleaned from computer simulation in deciphering RTK regulatory function. PMID: 28151998
We show that the decrease in PI(4,5)P2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plc11 and Grb2 correlate with patient survival PMID: 26212011
High FGFR2 expression was significantly associated with the depth of invasion, lymph-node metastasis, pathological stage, and distant metastasis or recurrent disease in gastric cancer. PMID: 28056982
fibroblast growth factor receptor 2 overexpression is correlated with decreased survival in most solid tumors, suggesting that the expression status of fibroblast growth factor receptor 2 is a valuable prognostic biomarker and a novel therapeutic target in human solid tumors. PMID: 28618942

Hide All

Involvement in disease

Crouzon syndrome (CS); Jackson-Weiss syndrome (JWS); Apert syndrome (APRS); Pfeiffer syndrome (PS); Beare-Stevenson cutis gyrata syndrome (BSTVS); Familial scaphocephaly syndrome (FSPC); Lacrimo-auriculo-dento-digital syndrome (LADDS); Antley-Bixler syndrome, without genital anomalies or disordered steroidogenesis (ABS2); Bent bone dysplasia syndrome (BBDS); Saethre-Chotzen syndrome (SCS)

Subcellular Location

Cell membrane; Single-pass type I membrane protein. Golgi apparatus. Cytoplasmic vesicle. Note=Detected on osteoblast plasma membrane lipid rafts. After ligand binding, the activated receptor is rapidly internalized and degraded.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein. Note=After ligand binding, the activated receptor is rapidly internalized and degraded.; [Isoform 3]: Cell membrane; Single-pass type I membrane protein. Note=After ligand binding, the activated receptor is rapidly internalized and degraded.; [Isoform 8]: Secreted.; [Isoform 13]: Secreted.

Protein Families

Protein kinase superfamily, Tyr protein kinase family, Fibroblast growth factor receptor subfamily

Database Links

HGNC: 3689

OMIM: 101200

KEGG: hsa:2263

STRING: 9606.ENSP00000410294

UniGene: Hs.533683

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA008645MA1HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in:hela whole cell lysate (20µg), HT29 whole cell lysate (20µg) All lanes: FGFR2 antibody at 1:1000 Secondary Goat polyclonal to human IgG at 1/40000 dilution Predicted band size:92.03, 86.13, 76.70, 28.29, 40.61, 79 kDa Observed band size:41 kDa Exposure time:120s IHC image of CSB-RA008645MA1HU diluted at 1:100 and staining in paraffin-embedded 肺癌 performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-human polymer IgG labeled by HRP and visualized using 0.05% DAB. IHC image of CSB-RA008645MA1HU diluted at 1:100 and staining in paraffin-embedded human liver tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-human polymer IgG labeled by HRP and visualized using 0.05% DAB.
Have Questions?	Leave a Message or Start an on-line Chat

FGFR2 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background